The study, published Aug. 18 in The New England Journal of Medicine, was funded by the National Institutes of Health and the Biomedical Advanced Research and Development Authority, an HHS office that develops responses to health security threats. It included 511 patients with a median age of 54.
“We were hoping that the use of COVID-19 convalescent plasma would achieve at least a 10% reduction in disease progression in this group, but instead the reduction we observed was less than 2%,” Clifton Callaway, MD, principal investigator for the study and professor of emergency medicine at the University of Pittsburgh, said in a news release.
The clinical trial was halted in February after an independent board concluded convalescent plasma was unlikely to help high-risk patients in emergency rooms.
Find the full study results here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
